JHS Svendgaard Laboratories Latest Share Price (JHS)
TODAY IN ONE LINE
JHS rose 1.7% on light volume, outperforming Nifty's 0.1% move, supported by recent strong earnings.
With a market cap of ₹71.76 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
JHS Svendgaard Laboratories flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 29.9% and Profit up 12.9%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.09x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest JHS Svendgaard Laboratories News
What changed recently?
Recent events, corporate actions, and announcements.
JHS Svendgaard Laboratories Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for JHS Svendgaard Laboratories Limited, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
JHS Svendgaard Laboratories Limited technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for JHS Svendgaard Laboratories Limited — derived from the latest tape, not yesterday's close.
JHS Svendgaard Laboratories Limited last traded at ₹8.29 with an intraday range of ₹8.1–₹8.43 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹8.29| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 9.11 | +0.82 | +9.85% |
| R3 | 8.78 | +0.49 | +5.87% |
| R2 | 8.60 | +0.31 | +3.78% |
| R1 | 8.45 | +0.16 | +1.89% |
| PIVOT | 8.27 | -0.02 | -0.20% |
| CURRENT | 8.29 | — | — |
| S1 | 8.12 | -0.17 | -2.09% |
| S2 | 7.94 | -0.35 | -4.18% |
| S3 | 7.79 | -0.50 | -6.07% |
| S4 | 7.46 | -0.83 | -10.05% |
JHS is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹8.1–₹8.32
Trading Inside opening range
JHS Svendgaard Laboratories Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for JHS Svendgaard Laboratories Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
JHS Svendgaard Laboratories Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹71.76 Cr. and reported EPS of ₹-0.22.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 92 | 102 ▲ 10.5% |
| Sales Growth YoY %Derived | 29.94% | 10.54% |
| Other Income | 3 | 3 ▲ 19.9% |
| Total Income | 95 | 105 ▲ 10.8% |
| 61 | 65 ▲ 6.9% | |
| Gross ProfitDerived | 31 | 36 ▲ 17.8% |
| Gross Margin %Derived | 33.65% | 35.86% |
| 35 | 34 ▼ 3.2% | |
| EBITDA (Operating Profit)Derived | -4 | 3 ▲ 165.2% |
| OPM %Derived | -4.36% | 2.57% |
| 6 | 8 ▲ 47.7% | |
| Profit Before Tax (PBT) | -13 | -2 ▲ 81.7% |
| 7 | -0 ▼ 105.1% | |
| Effective Tax %Derived | -57.47% | 16.07% |
| Total Profit for Period | -20 | -2 ▲ 90.2% |
| Less: Non-controlling Interests | — | — |
| Net Profit (Owner's PAT)Derived | -20 | -2 ▲ 90.2% |
| Net Profit Margin %Derived | -21.41% | -1.89% |
| PAT Growth YoY %Derived | -385.40% | 90.24% |
| Earnings Per Share (EPS ₹) | -2.31 | -0.22 ▲ 90.5% |
| Diluted Shares Outstanding (Cr) | 9 | 9 ▲ 2.1% |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▲ 27.9% |
| Total Expenses (incl. D&A & Interest) | 107 | 107 ▲ 0.0% |
| Material Cost % of RevenueDerived | 62.46% | 64.21% |
| Employee Cost % of RevenueDerived | 11.00% | 11.06% |
| Other Cost % of RevenueDerived | 27.01% | 22.23% |
| Interest Coverage (x)Derived | -21.17x | -5.68x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 143 | 124 ▼ 13.0% | 139 ▲ 12.1% | 101 ▼ 27.6% | 86 ▼ 14.4% | 96 ▲ 11.5% | 71 ▼ 26.4% | 92 ▲ 29.9% | 102 ▲ 10.5% | |
| Sales Growth YoY %Derived | — | -12.99% | 12.09% | -27.57% | -14.40% | 11.54% | -26.41% | 29.94% | 10.54% | |
| Other Income | 5 | 7 ▲ 33.8% | 14 ▲ 107.6% | 8 ▼ 45.5% | 9 ▲ 24.5% | 14 ▲ 53.3% | 4 ▼ 70.0% | 3 ▼ 33.3% | 3 ▲ 19.9% | |
| Total Income | 148 | 131 ▼ 11.4% | 153 ▲ 17.0% | 108 ▼ 29.2% | 96 ▼ 11.7% | 111 ▲ 15.6% | 75 ▼ 32.1% | 95 ▲ 26.3% | 105 ▲ 10.8% | |
90 | 87 ▼ 3.5% | 100 ▲ 14.7% | 68 ▼ 31.4% | 61 ▼ 11.5% | 66 ▲ 8.9% | 44 ▼ 33.0% | 61 ▲ 38.2% | 65 ▲ 6.9% | ||
| Gross ProfitDerived | 53 | 37 ▼ 29.2% | 39 ▲ 6.1% | 32 ▼ 17.9% | 26 ▼ 20.6% | 30 ▲ 17.8% | 27 ▼ 12.2% | 31 ▲ 16.2% | 36 ▲ 17.8% | |
| Gross Margin %Derived | 36.85% | 29.98% | 28.38% | 32.18% | 29.85% | 31.54% | 37.63% | 33.65% | 35.86% | |
39 | 38 ▼ 2.6% | 38 ▲ 0.0% | 31 ▼ 19.3% | 27 ▼ 12.8% | 39 ▲ 48.3% | 28 ▼ 30.1% | 35 ▲ 26.8% | 34 ▼ 3.2% | ||
| EBITDA (Operating Profit)Derived | 14 | -1 ▼ 104.3% | 2 ▲ 384.2% | 2 ▲ 14.7% | -1 ▼ 143.8% | -9 ▼ 982.0% | -1 ▲ 89.7% | -4 ▼ 327.9% | 3 ▲ 165.2% | |
| OPM %Derived | 9.64% | -0.47% | 1.20% | 1.90% | -0.98% | -9.46% | -1.32% | -4.36% | 2.57% | |
35 | 8 ▼ 76.7% | 0 ▼ 99.1% | 8 ▲ 11033.2% | 8 ▼ 0.6% | -10 ▼ 219.9% | 7 ▲ 167.2% | 6 ▼ 16.9% | 8 ▲ 47.7% | ||
| Profit Before Tax (PBT) | 38 | -2 ▼ 105.3% | -6 ▼ 185.7% | 1 ▲ 116.6% | 0 ▼ 89.4% | -22 ▼ 21304.3% | -3 ▲ 84.3% | -13 ▼ 264.8% | -2 ▲ 81.7% | |
12 | -0 ▼ 103.1% | -1 ▼ 91.7% | 1 ▲ 229.8% | 4 ▲ 367.5% | -5 ▼ 215.3% | 1 ▲ 112.4% | 7 ▲ 1042.6% | -0 ▼ 105.1% | ||
| Effective Tax %Derived | 32.19% | 18.47% | 12.39% | 97.09% | 4,264.47% | 23.19% | -18.35% | -57.47% | 16.07% | |
| Total Profit for Period | 26 | -2 ▼ 106.4% | -5 ▼ 191.2% | 1 ▲ 127.6% | -4 ▼ 419.5% | -17 ▼ 291.1% | -4 ▲ 75.8% | -20 ▼ 385.4% | -2 ▲ 90.2% | |
| Less: Non-controlling Interests | 0 | -1 ▼ 1139.6% | -3 ▼ 191.5% | 0 ▲ 105.0% | -0 ▼ 264.6% | -1 ▼ 452.4% | — ▲ 100.0% | — | — | |
| Net Profit (Owner's PAT)Derived | 26 | -1 ▼ 102.6% | -2 ▼ 190.7% | 1 ▲ 160.5% | -4 ▼ 438.2% | -15 ▼ 281.6% | -4 ▲ 73.8% | -20 ▼ 385.4% | -2 ▲ 90.2% | |
| Net Profit Margin %Derived | 18.20% | -0.55% | -1.42% | 1.19% | -4.70% | -16.07% | -5.73% | -21.41% | -1.89% | |
| PAT Growth YoY %Derived | — | -102.62% | -190.74% | 160.54% | -438.17% | -281.64% | 73.76% | -385.40% | 90.24% | |
| Earnings Per Share (EPS ₹) | 5.87 | -0.15 ▼ 102.6% | -0.44 ▼ 193.3% | 0.19 ▲ 143.2% | -0.62 ▼ 426.3% | -2.38 ▼ 283.9% | -0.52 ▲ 78.2% | -2.31 ▼ 344.2% | -0.22 ▲ 90.5% | |
| Diluted Shares Outstanding (Cr) | 4 | 4 ▲ 0.0% | 4 ▲ 0.0% | 6 ▲ 44.5% | 6 ▲ 0.8% | 6 ▲ 0.0% | 8 ▲ 20.8% | 9 ▲ 9.2% | 9 ▲ 2.1% | |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▲ 347.1% | 0 ▼ 52.0% | 0 ▲ 161.1% | 0 ▼ 10.8% | -0 ▼ 226.2% | 0 ▲ 146.9% | 0 ▲ 88.8% | 0 ▲ 27.9% | |
| Total Expenses (incl. D&A & Interest) | 109 | 133 ▲ 21.6% | 159 ▲ 19.6% | 107 ▼ 32.4% | 96 ▼ 11.0% | 132 ▲ 38.6% | 79 ▼ 40.7% | 107 ▲ 36.7% | 107 ▲ 0.0% | |
| Material Cost % of RevenueDerived | 57.59% | 65.84% | 68.26% | 63.54% | 62.24% | 58.25% | 57.65% | 62.46% | 64.21% | |
| Employee Cost % of RevenueDerived | 8.48% | 10.89% | 9.66% | 10.01% | 13.27% | 15.85% | 13.01% | 11.00% | 11.06% | |
| Other Cost % of RevenueDerived | 18.73% | 19.56% | 17.52% | 20.27% | 17.56% | 25.15% | 25.94% | 27.01% | 22.23% | |
| Interest Coverage (x)Derived | 9.41x | -7.43x | -3.63x | -4.30x | -5.66x | -15.90x | -15.83x | -21.17x | -5.68x |
JHS Svendgaard Laboratories segment analysis : revenue and profit mix.
Disclosed business segments at JHS Svendgaard Laboratories with their share of revenue and profit, switchable between consolidated and standalone reporting.
JHS Svendgaard Laboratories discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for JHS Svendgaard Laboratories Limited.
Our AI distills the core fundamental drivers supporting JHS Svendgaard Laboratories Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
JHS Svendgaard Laboratories Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Debt-to-equity ratio 0.0009x indicates minimal financial leverage and low default risk
Price-to-book 0.40x suggests significant undervaluation relative to tangible asset base
Latest quarterly profit surged 268% YoY, signaling strong operational turnaround momentum
TTM revenue growth 39.20% YoY demonstrates strong top-line expansion trajectory
Current ratio 1.95x provides adequate short-term liquidity for operational needs
Key Risks.
Negative ROE -1.11% and ROCE -0.78% reveal poor capital efficiency for shareholders
TTM net loss ₹15.2 Cr reflects persistent unprofitability despite revenue growth
Operating margin -4.80% indicates core business operations remain unprofitable
Latest quarterly sales declined 4.21% YoY, offsetting strong profit recovery gains
Operating cash flow negative ₹4.96 Cr in FY2025 signals weak cash generation capability
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
JHS Svendgaard Laboratories Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — JHS Svendgaard Laboratories Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
JHS Svendgaard Laboratories Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for JHS Svendgaard Laboratories Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
JHS Svendgaard Laboratories Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for JHS Svendgaard Laboratories Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in JHS Svendgaard Laboratories Limited stood at 69.8% of traded volume, against a 20-day average of 73.0%.
JHS Svendgaard Laboratories announcements: results, concalls, ratings, M&A.
Filings JHS Svendgaard Laboratories sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
JHS Svendgaard Laboratories files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 66 documents below.
Copy of Newspaper Publication
JHS Svendgaard Laboratories Limited has informed the Exchange about Copy of Newspaper Publication regarding Un-Audited Financial Results for the…
Outcome of Board Meeting
JHS Svendgaard Laboratories Limited has submitted to the Exchange, the Un-Audited financial results for the period ended Jun 30, 2026.
Shareholders meeting
JHS Svendgaard Laboratories Limited has submitted the Exchange a copy Srutinizers report along with Voting Results of Postal Ballot concluded on 29…
Shareholders meeting
JHS Svendgaard Laboratories Limited has informed the Exchange regarding Proceedings of Postal Ballot by Remote E-Voting Process by Members of the…
Certificate under SEBI (Depositories and Participants) Regulations, 2018
JHS Svendgaard Laboratories Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants)…
JHS Svendgaard Laboratories dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue JHS Svendgaard Laboratories has declared, sequenced by announce and record date.
JHS Svendgaard Laboratories corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About JHS Svendgaard Laboratories Limited: business, sector, key facts.
What JHS Svendgaard Laboratories Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
JHS Svendgaard Laboratories Limited operates in the Personal Care industry under the Fast Moving Consumer Goods sector, listed as NSE: JHS, BSE: 532771.
JHS Svendgaard Laboratories Limited
JHS Svendgaard Laboratories Limited is an Indian company primarily engaged in the manufacturing, trading, and sale of oral and dental care products for both adults and children. Their product portfolio is extensive and caters to a broad market segment.
The company's own brands include a diverse range of oral hygiene products such as toothbrushes, toothpastes, and mouthwashes. Beyond oral care, JHS also produces hand sanitizers, laundry detergents, room fresheners, and denture tablets. These products are marketed under various brand names, showcasing their strategic approach to market penetration and brand diversification. Some of their key brands include Dr. Gold, Dr. Fresh, Boots, Lavoris, Peanuts, and others.
A significant aspect of JHS's business model is contract manufacturing. They provide manufacturing services for other brands' oral care products, indicating a capacity for large-scale production and a strong position within the industry's supply chain. This diversified revenue stream contributes to the company's overall financial stability and resilience.
Furthermore, JHS Svendgaard Laboratories Limited extends its reach beyond the domestic Indian market through product exports. This international presence signifies a commitment to growth and expansion into global markets, enhancing brand visibility and revenue opportunities. The company's established distribution network and relationships with major retailers and pharmacies further strengthens its market position.
Founded in 1997 and headquartered in New Delhi, JHS Svendgaard Laboratories Limited has established itself as a prominent player in India's oral and dental care sector, leveraging both its own branded products and its contract manufacturing capabilities to achieve sustained growth and market share.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Bajaj Consumer Care (BAJAJCON) Share PricePeer
- Colgate Palmolive (India) (COLPAL) Share PricePeer
- Cupid (CUPID) Share PricePeer
- Dabur India (DABUR) Share PricePeer
- Emami (EMAMILTD) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about JHS Svendgaard Laboratories Limited (JHS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of JHS Svendgaard Laboratories Limited (JHS)?
The current share price of JHS Svendgaard Laboratories Limited (JHS) is ₹8.29. Today, the stock has gained by ₹0.14 (1.72%), trading in a range of ₹8.10 to ₹8.43. The stock opened at ₹8.32 with a trading volume of 21,985 shares.
02What is the 52-week high and low price of JHS Svendgaard Laboratories Limited stock?
The 52-week high price of JHS Svendgaard Laboratories Limited (JHS) is ₹13.90, while the 52-week low is ₹6.26. Currently trading at ₹8.29, the stock is 32.43% above its 52-week low and 40.36% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
03What is the dividend yield of JHS Svendgaard Laboratories Limited and when is the next dividend?
JHS Svendgaard Laboratories Limited offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹8.29, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
04How is JHS Svendgaard Laboratories Limited stock performing today in the market?
JHS Svendgaard Laboratories Limited stock opened at ₹8.32 and is currently trading at ₹8.29, showing a gain of ₹0.14 (1.72%). The intraday high is ₹8.43 and low is ₹8.10. The trading volume stands at 21,985 shares, indicating moderate market participation today.
05What is the market capitalization of JHS Svendgaard Laboratories Limited?
JHS Svendgaard Laboratories Limited has a market capitalization of ₹71.76 Cr., making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹8.29) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
06What is the ROE and ROCE of JHS Svendgaard Laboratories Limited?
JHS Svendgaard Laboratories Limited has a Return on Equity (ROE) of -1.11% and Return on Capital Employed (ROCE) of -0.78%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
07Which sector and industry does JHS Svendgaard Laboratories Limited belong to?
JHS Svendgaard Laboratories Limited operates in the Fast Moving Consumer Goods sector and belongs to the Personal Care industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
08What is the debt-to-equity ratio of JHS Svendgaard Laboratories Limited?
JHS Svendgaard Laboratories Limited has a debt-to-equity ratio of 0.09, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
The data, ratios and commentary about JHS Svendgaard Laboratories Limited (JHS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.